FGFR2 and neoplasm: In patients with cancers harboring FGFR2 fusion mutations, particularly advanced pancreatic ductal adenocarcinoma, erdafitinib administration inhibits the FGFR signaling pathway to suppress tumor growth, survival, and therapeutic resistance, ultimately leading to a significant reduction in tumor burden and improvement in clinical markers (Ng et al., 2022).